Swedish Orphan Biovitrum AB (publ) (BIOVF)
| Market Cap | 9.65B |
| Revenue (ttm) | 2.51B |
| Net Income (ttm) | 346.47M |
| Shares Out | n/a |
| EPS (ttm) | 0.99 |
| PE Ratio | 27.86 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 27.66 |
| Previous Close | 28.62 |
| Day's Range | 27.66 - 27.66 |
| 52-Week Range | 18.58 - 31.28 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 5, 2025 |
About BIOVF
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment... [Read more]
Full Company ProfileFinancial Performance
In 2023, BIOVF's revenue was 22.12 billion, an increase of 17.74% compared to the previous year's 18.79 billion. Earnings were 2.41 billion, a decrease of -8.68%.
Financial numbers in SEK Financial StatementsNews
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"),...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financi...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , April 4, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi") has, as previously announced, carried out a share issue of series C shares, which has resulted...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)
STOCKHOLM, Sweden , Aug. 15, 2023 /PRNewswire/ -- The Sobi® EGM was convened today on 15 August 2023. At the EGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Au...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2023 Results Conference Call July 18, 2023 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financia...
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , June 30, 2023 /PRNewswire/ -- As per 30 June 2023, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares. All shares are common shares.
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in adults and adolescents. Factor VIII inhibitor dev...
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.
CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings
CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. ...
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based dr...
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIO...
Sobi to Acquire CTI BioPharma
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commer...
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)
STOCKHOLM , May 9, 2023 /PRNewswire/ -- The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Adoption of the ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financ...
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , March 30, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be...
Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB
Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile of efanesoctocog alfa in previously treated patients under 12 years of age The completion of XTEND-Kids ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2022 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2022 Results Conference Call February 8, 2023 7:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Anders Ullman - Head of R&D...
Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023
STOCKHOLM, Nov. 18, 2022 /PRNewswire/ -- As previously communicated, Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi®), has announced that he will not be...
Swedish Orphan Biovitrum AB (publ)'s Chairman of the Board Håkan Björklund will not be available for re-election at the Annual General Meeting 2023
STOCKHOLM , Oct. 31, 2022 /PRNewswire/ -- Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi®), has today notified the Nomination Committee that he is not a...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2022 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q3 2022 Earnings Conference Call October 27, 2022 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Fina...